Slxn stock forecast sector rotation data in June points to

Sector rotation data in June points to tech mid-caps regaining investor favor, and SLXN stock forecast incorporates this inflow pattern as a possible acceleration lever for price appreciation through late 5 days ago · Stock forecasts and analyst price target predictions for Silexion Therapeutics Corp ( SLXN ) stock , with detailed revenue and earnings estimates. On July 9, 2025, Silexion Therapeutics announced positive preclinical results for SIL204, demonstrating significant efficacy in human lung cancer cell lines. The study highlighted SIL204’s potential as a versatile therapeutic for KRAS-driven cancers, supporting its innovative lipid-conjugated delivery system. The company is preparing for a Phase 2/3 clinical trial in 2026 and is conducting additional studies on a new KRAS mutation, which could establish SIL204 as a potential pan-KRAS treatment. SLXN stock forecast trends in June 2024 suggest the stock may outperform peers if quarterly EPS beats consensus by 5% or more, a scenario supported by management's optimism in current guidance calls.